Compare Lululemon Athletica Inc (LULU) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lululemon Athletica Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Lululemon Athletica Inc trades at $121.4 (market cap $14.26B), while Regeneron Pharmaceuticals Inc trades at $792 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 5.8× Lululemon Athletica Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Lululemon Athletica Inc pays none. Which is the better fit depends on your goals.
| LULU | REGN | |
|---|---|---|
Market Cap | $14.26B | $82.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $215.88 | $812.27 |
52-Week Low | $105.43 | $555.51 |
Enterprise Value | $14.89B | $76.77B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lululemon stock trades at $120.88, down 5.41% amid broader market weakness in the premium apparel sector. The company maintains strong fundamentals with a P/E of 10.17, net income margin of 13.03%, and consistent earnings beats. Technical indicators show a bullish moving average trend despite overbought RSI readings, with key resistance near $129.
Investment outlook remains positive given undervaluation metrics and international growth potential, though risks include U.S. demand softness and competitive pressures. Analyst consensus targets $129.29 with 41% buy ratings, suggesting moderate upside from current levels.
Regeneron Pharmaceuticals (REGN) trades at $797.99, down 1.24% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong fundamentals with a 27.86% net income margin and consistent earnings beats, though revenue growth is modest. Recent news highlights a class action lawsuit related to clinical trial disclosures, creating near-term sentiment headwinds despite positive analyst coverage.
Outlook remains supported by robust profitability and a bullish analyst consensus, but risks include legal overhangs and potential volatility from trial outcomes. The stock's valuation at a P/E of 19.72 appears reasonable given earnings strength, though investors should weigh litigation risks against fundamental resilience.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
